Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -186,566 | -162,555 | -93,710 | -119,025 | -402,727 |
| Depreciation Amortization | 13,109 | 9,345 | 5,887 | 2,553 | 2,325 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | 2,140 |
| Accounts receivable | 9,840 | 5,126 | 9,482 | 3,500 | -20,104 |
| Accounts payable and accrued liabilities | 26,853 | 2,822 | N/A | N/A | 13,312 |
| Other Working Capital | 104,663 | 95,750 | 129,932 | 2,903 | -19,459 |
| Other Operating Activity | -100,119 | -20,256 | -59,392 | 14,917 | 79,130 |
| Operating Cash Flow | $-132,220 | $-69,768 | $-7,801 | $-95,152 | $-345,383 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -172,441 | -240,688 | -153,485 | -81,029 | 26,132 |
| PPE Investments | -43,905 | -21,959 | -18,179 | -14,096 | -24,832 |
| Purchase Of Investment | -37,062 | -10,220 | -9,600 | N/A | -14,339 |
| Sale Of Investment | 79,842 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -5,555 | -4,155 | 0 | 0 | 0 |
| Investing Cash Flow | $-179,121 | $-277,022 | $-181,264 | $-95,125 | $-13,039 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 600,508 | 110,710 | 91,517 | 55,648 | 365,072 |
| Other Financing Activity | -236 | -149 | -91 | -33 | 314,234 |
| Financing Cash Flow | $600,272 | $110,561 | $91,426 | $55,615 | $679,306 |
| Exchange Rate Effect | 1,119 | 239 | -198 | -623 | -165 |
| Beginning Cash Position | 436,244 | 436,244 | 436,244 | 436,244 | 115,525 |
| End Cash Position | 726,294 | 200,254 | 338,407 | 300,959 | 436,244 |
| Net Cash Flow | $290,050 | $-235,990 | $-97,837 | $-135,285 | $320,719 |
| Free Cash Flow | |||||
| Operating Cash Flow | -132,220 | -69,768 | -7,801 | -95,152 | -345,383 |
| Capital Expenditure | -43,905 | -21,959 | -18,179 | -14,096 | -24,832 |
| Free Cash Flow | -176,125 | -91,727 | -25,980 | -109,248 | -370,215 |